A heart valve dedicated for aortic regurgitation: Review of technology and early clinical experience with the transfemoral Trilogy system
Why the study?
Many patients with aortic regurgitation cannot undergo surgical replacement due to adverse surgical risk, and transcatheter valve implantation with most available prostheses has suboptimal success and outcomes.
Design
Expert review
Authors
Discussion
Loading...
Member takes
Implication
Trilogy may offer an option for high-risk AR; leaves open need for prospective comparative data.
Key Points
- To review the technical features, implantation technique, and early clinical evidence supporting the transfemoral JenaValve Trilogy system for patients with aortic regurgitation.
- Reviewed mechanical specifications and procedural deployment guidelines for the transfemoral Trilogy transcatheter valve system.
- Evaluated available clinical data from European commercial approval and ongoing United States investigational protocols, alongside illustrative patient cases.
- The Trilogy system achieves anatomical fixation by utilizing dedicated locator clips that directly grasp native valve leaflets, eliminating reliance on annular calcification.
- Early clinical experience demonstrates feasible transfemoral valve deployment and effective regurgitation reduction in patients ineligible for standard surgical valve replacement.
Structured PICO
P
Population
Patients with aortic regurgitation who are not candidates for surgical aortic valve replacement due to an adverse surgical risk profile
I
Intervention
JenaValve Trilogy system (transfemoral delivery)
The JenaValve Trilogy system offers a dedicated transcatheter option for high-surgical-risk patients with aortic regurgitation.
Cite This Study
Baumbach et al. (2023) studied this question.